Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 7/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23649574 | 0.84 | CYP1A2 (0.38) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL3187683 | 0.83 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL13868824 | 0.83 | CYP2D6 (0.50) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL4365780 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL430340 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL27583111 | 0.80 | CYP2D6 (0.47) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL9683891 | 0.78 | CYP2D6 (0.46) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL20184852 | 0.78 | CYP2D6 (0.46) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL11426254 | 0.78 | CYP2D6 (0.50) | CYP1A2CYP2D6MAPTKMT2AKIF11 | |
| SCHEMBL17582896 | 0.78 | CYP2D6 (0.46) | CYP1A2CYP2D6MAPTKMT2AKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116896985-A | Method for controlling harmful arthropods or harmful linear animals by using levoambamine | 住友化学株式会社 | 2023-10-17 | — | — | CN | disclosed |
| US-7452908-B2 | Amide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-11-18 | — | — | US | disclosed |
| WO-2007124459-A2 | INDEX-CONTRASTING-PHOTOACTIVE POLYMERIZABLE MATERIALS, AND ARTICLES AND METHODS USING SAME | INPHASE TECHNOLOGIES, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070248890-A1 | Index Contrasting-Photoactive Polymerizable Materials, and Articles and Methods Using Same | INPHASE TECHNOLOGIES, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-6809108-B1 | SELECTIVE MUSCARINIC M3 RECEPTOR ANTAGONTS; REDUCED SIDE EFFECTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20040204369-A1 | Novel amide derivatives | MSD K.K. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1213281-B1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204369-A1 | Novel amide derivatives | CHRM3, CHRM1, CHRM2 | CYP1A2 676/4885CYP2D6 1047/4885MAPT 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.